| Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised … AMM Eggermont, CU Blank, M Mandalà, GV Long, VG Atkinson, S Dalle, ... The lancet oncology 22 (5), 643-654, 2021 | 307 | 2021 |
| Selection of CD8+ PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells T Inozume, K Hanada, QJ Wang, M Ahmadzadeh, JR Wunderlich, ... Journal of immunotherapy 33 (9), 956-964, 2010 | 243 | 2010 |
| Melanoma cells control antimelanoma CTL responses via interaction between TIGIT and CD155 in the effector phase T Inozume, T Yaguchi, J Furuta, K Harada, Y Kawakami, S Shimada Journal of Investigative Dermatology 136 (1), 255-263, 2016 | 173 | 2016 |
| Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041) N Yamazaki, T Takenouchi, M Fujimoto, H Ihn, H Uchi, T Inozume, ... Cancer chemotherapy and pharmacology 79, 651-660, 2017 | 92 | 2017 |
| IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells T Inozume, K Hanada, QJ Wang, JC Yang Journal of immunotherapy 32 (2), 109-117, 2009 | 74 | 2009 |
| A case of metastatic extramammary Paget’s disease responding to trastuzumab plus paclitaxel combination therapy F Hanawa, T Inozume, K Harada, T Kawamura, N Shibagaki, S Shimada Case Reports in Dermatology 3 (3), 223-227, 2011 | 67 | 2011 |
| CD271 on melanoma cell is an IFN-γ-inducible immunosuppressive factor that mediates downregulation of melanoma antigens J Furuta, T Inozume, K Harada, S Shimada Journal of Investigative Dermatology 134 (5), 1369-1377, 2014 | 64 | 2014 |
| Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity H Mitsui, T Inozume, R Kitamura, N Shibagaki, S Shimada Journal of investigative dermatology 126 (8), 1804-1812, 2006 | 62 | 2006 |
| Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses T Yaguchi, A Kobayashi, T Inozume, K Morii, H Nagumo, H Nishio, T Iwata, ... Cellular & molecular immunology 15 (11), 953-962, 2018 | 61 | 2018 |
| PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes J Nagasaki, T Inozume, N Sax, R Ariyasu, M Ishikawa, K Yamashita, ... Cell reports 38 (5), 2022 | 55 | 2022 |
| T cell immune responses against melanoma and melanocytes in cancer and autoimmunity Y Kawakami, Y Suzuki, T Shofuda, Y Kiniwa, T Inozume, K Dan, T Sakurai, ... Pigment Cell Research 13, 163-169, 2000 | 54 | 2000 |
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised … A Bottomley, C Coens, J Mierzynska, CU Blank, M Mandalà, GV Long, ... The lancet oncology 22 (5), 655-664, 2021 | 53 | 2021 |
| Prognosis of patients with adult T‐cell leukemia/lymphoma in Japan: a nationwide hospital‐based study Y Imaizumi, M Iwanaga, K Nosaka, K Ishitsuka, K Ishizawa, S Ito, ... Cancer Science 111 (12), 4567-4580, 2020 | 47 | 2020 |
| Overexpression of GRIM-19 in cancer cells suppresses STAT3-mediated signal transduction and cancer growth T Okamoto, T Inozume, H Mitsui, M Kanzaki, K Harada, N Shibagaki, ... Molecular cancer therapeutics 9 (8), 2333-2343, 2010 | 47 | 2010 |
| TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment S Kawashima, T Inozume, M Kawazu, T Ueno, J Nagasaki, E Tanji, ... Journal for immunotherapy of cancer 9 (11), 2021 | 46 | 2021 |
| Molecular identification of an MHC-independent ligand recognized by a human α/β T-cell receptor K Hanada, QJ Wang, T Inozume, JC Yang Blood, The Journal of the American Society of Hematology 117 (18), 4816-4825, 2011 | 39 | 2011 |
| Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019 Y Nakamura, J Asai, H Igaki, T Inozume, K Namikawa, A Hayashi, ... The Journal of Dermatology 47 (2), 89-103, 2020 | 36 | 2020 |
| Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: a … Y Umeda, S Yoshikawa, Y Kiniwa, T Maekawa, O Yamasaki, T Isei, ... European Journal of Cancer 157, 361-372, 2021 | 32 | 2021 |
| Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective … Y Nakamura, K Namikawa, S Yoshikawa, Y Kiniwa, T Maekawa, ... ESMO open 6 (6), 100325, 2021 | 29 | 2021 |
| Novel melanoma antigen, FCRL/FREB, identified by cDNA profile comparison using DNA chip are immunogenic in multiple melanoma patients T Inozume, Y Matsuzaki, S Kurihara, T Fujita, A Yamamoto, H Aburatani, ... International journal of cancer 114 (2), 283-290, 2005 | 26 | 2005 |
